Sofosbuvir plus ribavirin in Asian patients with chronic genotype 2 hepatitis C virus infection: history of a success?

Liver International

Volumn 36, Issue 8, 2016, Pages 1093-1095

  Sáez Royuela, Federico ^a   Badia, Ester ^a  

^a HOSPITAL UNIVERSITARIO DE BURGOS   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

INTERLEUKIN 28B; RIBAVIRIN; SOFOSBUVIR;

ANTIVIRAL THERAPY; ASIAN; CHRONIC HEPATITIS C; COMBINATION DRUG THERAPY; DNA POLYMORPHISM; DRUG EFFICACY; DRUG RESPONSE; DRUG SAFETY; EDITORIAL; HEPATITIS C VIRUS GENOTYPE 2; HUMAN; LIVER CIRRHOSIS; MULTICENTER STUDY (TOPIC); PHARMACOGENETICS; PHASE 3 CLINICAL TRIAL (TOPIC); TAIWAN; TREATMENT DURATION;

EID: 84978849203     PISSN: 14783223     EISSN: 14783231     Source Type: Journal    
DOI: 10.1111/liv.13138     Document Type: Editorial

References (14)

1. European Association for the Study of the Liver. EASL clinical practice guidelines: management of hepatitis C virus infection. J Hepatol 2011; 55: 245–64.
2. Omata M, Nishiguchi S, Ueno Y, et al. Sofosbuvir plus ribavirin in Japanese patients with chronic genotype 2 HCV infection: an open-label, phase 3 trial. J Viral Hepat 2014; 21: 762–8.
3. Waldenström J, Färkkilä M, Rembeck K, et al. Short interferon and ribavirin treatment for HCV genotype 2 or 3 infection: NORDynamIC trial and real-life experience. Scand J Gastroenterol 2016; 51: 337–43.
4. Marotta P, Bailey R, Elkashab M, et al. Real-world effectiveness of peginterferon α-2b plus ribavirin in a Canadian cohort of treatment-naïve chronic hepatitis C patients with genotypes 2 or 3: results of the PoWer and RediPEN studies. Eur J Clin Microbiol Infect Dis 2016; 35: 597–609.
5. European Association for Study of Liver. EASL Clinical Practice Guidelines: management of hepatitis C virus infection. J Hepatol 2014; 60: 392–420.
6. Liang TJ, Ghany MG. Current and future therapies for hepatitis C virus infection. N Engl J Med 2013; 369: 679–80.
7. European Association for Study of Liver. EASL Recommendations on Treatment of Hepatitis C 2015. J Hepatol 2015; 63: 199–236.
8. Lawitz E, Mangia A, Wyles D, et al. Sofosbuvir for previously untreated chronic hepatitis C infection. N Engl J Med 2013; 368: 1878–87.
9. Jacobson IM, Gordon SC, Kowdley KV, et al. Sofosbuvir for hepatitis C genotype 2 or 3 in patients without treatment options. N Engl J Med 2013; 368: 1867–77.
10. Zeuzem S, Dusheiko GM, Salupere R, et al. Sofosbuvir and ribavirin in HCV genotypes 2 and 3. N Engl J Med 2014; 370: 1993–2001.
11. Foster GR, Afdhal N, Roberts SK, et al. Efficacy of sofosbuvir plus ribavirin with or without peginterferon-alfa in patients with hepatitis C virus genotype 3 infection and treatment-experienced patients with cirrhosis and hepatitis C virus genotype 2 infection. Gastroenterology 2015; 149: 1462–70.
12. Liakina V, Hamid S, Tanaka J, et al. Historical epidemiology of hepatitis C virus (HCV) in select countries - volume 3. J Viral Hepat 2015; 22(Suppl 4): 4–20.
13. Ahn SH, Lim Y-S, Lee K-S, et al. A phase 3b study of sofosbuvir plus ribavirin in treatment-na.ve and treatment-experienced Korean patients chronically infected with genotype 2 Hepatitis C virus. J Viral Hepat 2016; 23: 358–65.
14. Kao JH, Chien RN, Chang TT, et al. A phase 3b study of sofosbuvir plus ribavirin in Taiwanese patients with chronic genotype 2 hepatitis C virus infection. Liver Int 2016; 36: 1101–7.